Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

The 12-month pilot trial treated 31 subjects with ifetroban and 10 with placebo.

Rhea-AI Summary

Cumberland Pharmaceuticals (CPIX) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis. In the 12-month pilot trial, ifetroban was generally well tolerated. No serious adverse event was assessed by the medical monitor as related to study drug. Gastrointestinal adverse events were more frequent with ifetroban than placebo; most were mild and resolved. Bleeding-related adverse events increased modestly and were predominantly mild.

Efficacy conclusions cannot be drawn because of the sample size and exploratory analysis; the trial was not designed or powered to evaluate efficacy. Limited disease progression in both groups also reduced its ability to detect a treatment difference. Cumberland plans to submit the clinical study report to the FDA and complete biomarker and extension-study cardiac imaging evaluations to inform further development decisions.

4 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Minor pointIfetroban was generally well tolerated, with a safety profile consistent with prior experience.
• Minor pointNo serious adverse event during 12-month treatment was assessed by the medical monitor as study-drug related.
• Minor point. Forward-looking: it has not happened yet and may not happen.Biomarker and extension-study cardiac imaging evaluations are planned to inform further development decisions.
• Minor point. Forward-looking: it has not happened yet and may not happen.Clinical study report submission to the FDA is planned.

Negative

• Moderate pointEfficacy conclusions are precluded by sample size and exploratory analysis; the trial was not powered to evaluate efficacy.
• Minor pointLimited disease progression in both groups reduced the trial's ability to detect a treatment difference.
• Minor pointGastrointestinal adverse events were more frequent with ifetroban than placebo; most were mild and resolved.
• Minor pointBleeding-related adverse events increased modestly with ifetroban and were predominantly mild.

Argus 15 min delay 2 alerts

-12.13% vs previous close $7.46 last price 0.7x rel. volume Open Argus

Details

Market move: CPIX -12.13% vs previous close. Phase 2a clinical data

-1.3% Trough Tracked

$7.00 – $9.40 Day Range

$111.77M Mkt Cap at Last Price

On Oct 23, the day this news came out, the latest delayed price for CPIX is 12.13% below the previous close. Argus tracked a trough of -1.3% from its starting point during tracking. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $7.46.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Ifetroban-treated subjects: 31 subjects Placebo subjects: 10 subjects Treatment period: 12 months +1 more

Ifetroban-treated subjects

31 subjects

Phase 2a ASSIST-SSc trial

Placebo subjects

10 subjects

Phase 2a ASSIST-SSc trial

Treatment period

12 months

Phase 2a ASSIST-SSc trial

Serious adverse events assessed as related to study drug

0

During the 12-month treatment period

Key Terms

systemic sclerosis, pulmonary arterial hypertension, treatment emergent adverse events, open-label extension

4 terms

systemic sclerosis medical

"patients with systemic sclerosis ("SSc")"

Systemic sclerosis is a chronic autoimmune disease where the body's repair system overreacts, causing hardening and tightening of skin and internal organs much like scar tissue spreading beyond a wound. It matters to investors because it creates a clear medical need for new treatments, influences the size and urgency of clinical trials, and affects regulatory scrutiny, pricing power, and long-term healthcare costs tied to any therapy or diagnostic that proves effective.

pulmonary arterial hypertension medical

"patients with either diffuse cutaneous (dcSSc) or pulmonary arterial hypertension"

Pulmonary arterial hypertension is a progressive medical condition in which the arteries that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure in the lung circulation and extra strain on the heart — like a pump working against clogged pipes. For investors, it matters because the condition defines the need, market size, clinical trial design, regulatory hurdles and potential revenue or risk for companies developing drugs, devices or diagnostics to treat or manage it.

treatment emergent adverse events medical

"frequency of treatment emergent adverse events between treatment groups"

Treatment emergent adverse events are any new or worsened medical problems that appear after a patient starts a drug or medical intervention during a clinical trial. Investors care because the number, severity, and frequency of these events influence safety profiles, regulatory approval chances, and market acceptance; think of them like unexpected problems that crop up after installing a software update—minor ones may be manageable, but serious or common issues can stall or derail the product.

open-label extension medical

"patients continuing on the open-label extension"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ifetroban was well tolerated in patients with systemic sclerosis

NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis ("SSc"). These results support the safety and tolerability of ifetroban in this rare disease population. Cumberland will next complete correlative biomarker studies using specimens collected during the trial, along with an evaluation of cardiac imaging from patients continuing on the open-label extension.

SSc is a rare autoimmune disease characterized by excess collagen deposition resulting in skin thickening, cardiovascular disease, gastrointestinal problems, and more, and affects approximately 100,000 individuals in the U.S. Current therapies target specific manifestations of SSc, and approved options are available for SSc-associated interstitial lung disease. However, there is no approved therapy directed at the primary cardiac issues associated with SSc. Both cardiac and pulmonary manifestations remain among the leading causes of mortality for patients with the disease.

Ifetroban is a once-daily oral medication that works by blocking the thromboxane receptor, which plays a key role in inflammation, vascular dysfunction and fibrosis. In preclinical models of pulmonary arterial hypertension and heart disease, ifetroban treatment was associated with a reduction in fibrosis and provided cardioprotective effects (West 2016). A delay or inhibition of tissue fibrosis and improved cardiac function could provide significant improvement in quality of life for SSc patients. These preclinical results were foundational to the development of this Phase 2a clinical trial.

The 12-month Phase 2a ASSIST-SSc trial (NCT02682511) was a pilot trial to evaluate the safety of oral ifetroban in patients with SSc. Patients with either diffuse cutaneous (dcSSc) or pulmonary arterial hypertension (SSc-PAH) manifestations were randomized to receive ifetroban or matching placebo. A total of 31 subjects received ifetroban (22 dcSSc and 9 SSc-PAH) and 10 subjects received placebo (9 dcSSc and 1 SSc-PAH). Safety was evaluated by the frequency of treatment emergent adverse events between treatment groups. Exploratory efficacy endpoints were evaluated by SSc cohort to assess the effect of ifetroban on multiple aspects of SSc disease, including cardiovascular, pulmonary, skin, activity and quality of life.

Ifetroban was generally well tolerated, with a safety profile consistent with prior experience. As in prior ifetroban studies, gastrointestinal adverse events were more frequent in the ifetroban group than in the placebo group; the majority were mild and resolved. A modest increase in bleeding-related adverse events was also observed with ifetroban, in keeping with its mechanism as a thromboxane prostanoid receptor antagonist, and these events were predominantly mild. No serious adverse event during the 12-month treatment period was assessed by the medical monitor as related to study drug.

The majority of subjects in both treatment groups showed limited disease progression during the study, which reduced the ability of a trial of this size to detect a treatment difference. This Phase 2a trial was not designed or powered to evaluate efficacy, and the sample size and exploratory analytic approach preclude efficacy conclusions.

Cumberland has reviewed the results from both the dcSSc and SSc-PAH cohorts with clinical experts in SSc. As next steps, the Company plans to submit the clinical study report to the U.S. Food and Drug Administration ("FDA") and to also complete correlative biomarker studies using specimens collected during the trial, along with an evaluation of cardiac imaging from patients continuing on the open-label extension. Those findings will inform Cumberland's decision on the further development of ifetroban in SSc.

About Systemic Sclerosis (SSc)

SSc is a rare autoimmune connective tissue disease which is characterized by rapidly progressing fibrosis and atrophy in the musculoskeletal system and internal organs including the lungs, heart, gastrointestinal tract and kidneys. While approved therapies exist for certain pulmonary manifestations, no therapy is currently approved to treat or prevent the primary cardiac involvement of SSc.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new therapies to address significant unmet medical needs and improve the quality of patient care. The Company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are also evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

For more information, please visit www.cumberlandpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, the risks inherent in clinical development, regulatory review and the commercialization of ifetroban and other pipeline or CET-supported assets, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the U.S. Securities and Exchange Commission ("SEC"). There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-assist-ssc-trial-top-line-results-302918449.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cumberland Pharmaceuticals' ASSIST-SSc trial show about ifetroban safety?

Ifetroban was generally well tolerated, and no serious adverse event during the 12-month treatment period was assessed by the medical monitor as related to study drug. Gastrointestinal adverse events were more frequent than with placebo, with most mild and resolved. Bleeding-related adverse events increased modestly and were predominantly mild.

Did Cumberland Pharmaceuticals' ASSIST-SSc trial establish ifetroban efficacy?

No efficacy conclusions can be drawn from this Phase 2a trial because of its sample size and exploratory analytic approach. It was not designed or powered to evaluate efficacy. Most subjects in both treatment groups showed limited disease progression, reducing the ability to detect a treatment difference.

Who participated in Cumberland Pharmaceuticals' ASSIST-SSc trial?

Patients with diffuse cutaneous systemic sclerosis or systemic sclerosis-associated pulmonary arterial hypertension were randomized to ifetroban or matching placebo. The ifetroban group included 22 subjects with diffuse cutaneous disease and 9 with pulmonary arterial hypertension; the placebo group included 9 and 1, respectively.